DelveInsights, Tezacaftor (VX-661) + Ivacaftor, Launch Insights, 2017 report provides comprehensive insights about the Tezacaftor (VX-661) + Ivacaftor's launch. The report covers all the indications for which the Tezacaftor (VX-661) + Ivacaftor is being developed and also provides the competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning.
The report will provide a clear picture of market positioning of the upcoming launch of Tezacaftor (VX-661) + Ivacaftor and will also provide the insight about how Tezacaftor (VX-661) + Ivacaftor will evolve in the market as well as within its respective class.Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.
Attribute analysis carried out by our analysts helps in understanding how the upcoming launch scores itself in comparison to other competitors (both marketed and pipeline). The scoring and analysis has been based upon scrutinizing data from all key clinical trials for the product. A head to head comparison with marketed products if available is scanned thoroughly. Further, analyzing data of other competitors with regards to the product also assists in proper scoring of the product in its space.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Detailed product description including its chemical properties, molecule type and mechanism of action
Detailed description of non-clinical and clinical studies for all the indications
Patent expiry analysis of the drug along with other competitors in the market
Forecasted sales till 2022
Tezacaftor (VX-661) + Ivacaftor market positioning analysis
Tezacaftor (VX-661) + Ivacaftor class share evolution
Tezacaftor (VX-661) + Ivacaftor Overview
Tezacaftor (VX-661) + Ivacaftor of action
Product Developmental Activities
Mergers & Acquisitions
Tezacaftor (VX-661) + Ivacaftor Market Evolution
Tezacaftor (VX-661) + Ivacaftor Class Share Evolution
Tezacaftor (VX-661) + Ivacaftor Market Positioning
Patent Expiry Analysis
Competitive Landscape for the Tezacaftor (VX-661) + Ivacaftor in major indications
List of Table
Table 1: Tezacaftor (VX-661) + Ivacaftor, Heat Map
Table 2: Clinical Trial Landscape
Table 3: Clinical Efficacy Data from Cross Trials
Table 4: Competitive Landscape for Tezacaftor (VX-661) + Ivacaftor in Indication 1
Table 5: Competitive Landscape for Tezacaftor (VX-661) + Ivacaftor in Indication 2
List of Chart
Figure 1: Tezacaftor (VX-661) + Ivacaftor Developmental Milestones
Figure 2: Tezacaftor (VX-661) + Ivacaftor Sales Forecast till 2022
Figure 3: Tezacaftor (VX-661) + Ivacaftor Class Share Evolution
Figure 4: Comparative analysis of Tezacaftor (VX-661) + Ivacaftor with marketed products in the same class
Figure 5: Patent Expiry Analysis
Make an enquiry before buying this Report
Please fill the enquiry form below.